ENZON PHARM (EZ1.SG)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon… Read more
ENZON PHARM (EZ1.SG) (EZ1) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.125x
Based on the latest financial reports, ENZON PHARM (EZ1.SG) (EZ1) has a cash flow conversion efficiency ratio of 1.125x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.04 Million) by net assets (€-923.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ENZON PHARM (EZ1.SG) - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how ENZON PHARM (EZ1.SG)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ENZON PHARM (EZ1.SG) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENZON PHARM (EZ1.SG) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RH Inc.
BE:RS1
|
-0.048x |
|
LIQUID META CAPITAL HLDGS
F:N5F
|
N/A |
|
Patriot Gold Corp
PINK:PGOL
|
0.226x |
|
BEL FUSE-B
BE:BF2B
|
0.075x |
|
iWallet Corporation
PINK:IWAL
|
0.015x |
|
GATX (GAX.SG)
STU:GAX
|
0.057x |
|
Bucur Obor SA
RO:BUCU
|
N/A |
|
Yari Minerals Ltd
AU:YAR
|
0.000x |
Annual Cash Flow Conversion Efficiency for ENZON PHARM (EZ1.SG) (2016–2024)
The table below shows the annual cash flow conversion efficiency of ENZON PHARM (EZ1.SG) from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €3.01 Million | €1.12 Million | 0.373x | +0.18% |
| 2023-12-31 | €3.50 Million | €1.30 Million | 0.372x | +292.49% |
| 2022-12-31 | €3.41 Million | €-659.00K | -0.193x | -87.94% |
| 2021-12-31 | €4.87 Million | €-501.00K | -0.103x | -99.33% |
| 2020-12-31 | €7.36 Million | €-380.00K | -0.052x | -104.53% |
| 2019-12-31 | €6.05 Million | €6.91 Million | 1.140x | +1848.23% |
| 2018-12-31 | €14.99 Million | €-978.00K | -0.065x | -109.22% |
| 2017-12-31 | €9.14 Million | €6.47 Million | 0.708x | +181.30% |
| 2016-12-31 | €10.33 Million | €2.60 Million | 0.252x | -- |